|
|
|
| Uric acid promotes the proliferation and migration of prostate cancer cell through down-regulating the expression of lncRNA MIR22HG#br# |
| LI Ansu1， SHAO Shihe1， WANG Xiuping1， ZHU Huazi1， HU Jianpeng2 |
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Urology Surgery, Affliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002, China）
|
|
|
|
| Guide |
|
Abstract ［Abstract］Objective： To investigate whether uric acid （UA) regulates the proliferation and migration of prostate cancer cells through lncRNA MIR22HG. Methods： Prostate cancer DU145 cells were divided into control group and UA (400 μmol/L) treatment group, transfected with siMIR22HG or siNC group, and transfected with pcDNAMIR22HG or pcDNA group, and UA+pcDNA-MIR22HG or UA+pcDNA group. The expression of MIR22HG in DU145 cells was detected by qRT-PCR, the cell proliferation ability was detected by CCK-8, the expression of cell cycle related factors （Cyclin D1, CDK4 and P21) was detected by Western blotting, and the cell migration ability was measured by Transwell. Results： Compared with the control group, after being treated with 400 μmol/L uric acid, the expression of MIR22HG in DU145 cells decreased significantly （P<0.01), the viability and migration ability of prostate cancer DU145 cells increased significantly （P<0.01), the expression levels of Cyclin D1 and CDK4 protein increased significantly （P<0.01), and the expression level of P21 protein decreased significantly （P<0.01). Compared with the corresponding control group, downregulation of MIR22HG could significantly promote the proliferation and migration of prostate cancer DU145 cells （P<0.01), while upregulation of MIR22HG could inhibit their proliferation and migration （P<0.01). At the same time, overexpression of MIR22HG could reverse the promoting effect of uric acid on the proliferation and migration of DU145 cells （P<0.01). Conclusion： Uric acid can promote the proliferation and migration of prostate cancer cells, which may be attributed to the down regulation of MIR22HG expression.
|
|
Received: 10 February 2022
|
| Fund: |
|
|
|
［1］Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021［J］. CA Cancer J Clin, 2021, 71(1): 7-33.
［2］Sandhu S, Moore CM, Chiong E, et al. Prostate cancer［J］. Lancet, 2021, 398(10305): 1075-1090.
［3］Siroosbakht S, Rezakhaniha S, Namdari F, et al. Is there relationship between serum uric acid levels and lower urinary tract symptoms, prostate volume, and PSA in men without cancer? A prospective populationbased study［J］. Andrologia, 2021, 53(10): e14200.
［4］Fini MA, Elias A, Johnson RJ, et al. Contribution of uric acid to cancer risk, recurrence, and mortality［J］. Clin Transl Med, 2012, 1(1): 1-15.
［5］Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidantand radicalcaused aging and cancer: a hypothesis［J］. Proc Natl Acad Sci U S A, 1981, 78(11): 6858-6862.
［6］Chen MM, Meng LH. The double faced role of xanthine oxidoreductase in cancer［J］. Acta Pharmacol Sin, 2022, 43(7): 1623-1632.
［7］Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and mechanisms［J］. Cell, 2013, 154(1): 26-46.
［8］周新童,任天宇,党胜春. 长链非编码RNA AL139147.1在胃癌中的表达及对MKN45胃癌细胞生长的影响［J］. 江苏大学学报（医学版）, 2021, 31(1): 51-55.
［9］张鹤腾,唐银炳,谢文杰,等. 长链非编码RNA SPATA3AS1在胃癌中的表达及意义［J］. 江苏大学学报（医学版）, 2021, 31(6): 489-495.
［10］Statello L, Guo C, Chen L, et al. Gene regulation by long noncoding RNAs and its biological functions［J］. Nat Rev Mol Cel Bio, 2021, 22(2): 96-118.
［11］Shen H, Weng XD, Yang D, et al. Long noncoding RNA MIR22HG is downregulated in prostate cancer［J］. Math Biosci Eng, 2019, 17(2): 1776-1786.
［12］Sangkop F,Singh G, Rodrigues E, et al. Uric acid: a modulator of prostate cells and activin sensitivity［J］. Mol Cel Biochem, 2016, 414(1-2): 187-199.
［13］Wu L,Yang W, Zhang Y, et al. Elevated serum uric acid is associated with poor survival in advanced HCC patients and febuxostat improves prognosis in HCC rats［J］. Front Pharmacol, 2021, 12: 778890.
［14］Stotz M, Szkandera J, Seidel J, et al. Evaluation of uric acid as a prognostic bloodbased marker in a large cohort of pancreatic cancer patients［J］. PLoS One, 2014, 9(8): e104730.
［15］Dhankhar R, Dahiya K, Sharma TK, et al. Diagnostic significance of adenosine deaminase, uric acid and Creactive protein levels in patients of head and neck carcinoma［J］. Clin Lab, 2011, 57(9-10): 795-798.
［16］Kolonel LN, Yoshizawa C, Nomura AM, et al. Relationship of serum uric acid to cancer occurrence in a prospective male cohort［J］. Cancer Epidemiol Biomarkers Prev, 1994, 3(3): 225-228.
［17］Hammarsten J, Damber JE, Peeker R, et al. A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer［J］. Cancer Epidemiol, 2010, 34(5): 574-579.
［18］Wang A, Barber JR, Tin A, et al. Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis Risk in Communities（ARIC) Study［J］. Cancer Epidemiol Biomarkers Prev, 2019, 28(7): 1259-1261.
［19］Benli E, Cirakoglu A, Ayyldz SN, et al. Comparison of serum uric acid levels between prostate cancer patients and a control group［J］. Cent European J Urol, 2018, 71(2): 242-247.
［20］Slack FJ, Chinnaiyan AM. The role of noncoding RNAs in oncology［J］. Cell, 2019, 179(5): 1033-1055.
［21］Li P, Xu H, Yang L, et al. E2F transcription factor 2activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoidinduced protein kinase 1［J］. Cell Death Dis, 2022, 13(1): 77.
［22］Zhang D, Zou X, Cao C, et al. Identification and functional characterization of long noncoding RNA MIR22HG as a tumor suppressor for hepatocellular carcinoma［J］. Theranostics, 2018, 8(14): 3751-3765.
［23］Deng X, Ye D, Hua K, et al. MIR22HG inhibits breast cancer progression by stabilizing LATS2 tumor suppressor［J］. Cell Death Dis, 2021, 12(9): 810.
［24］Xu J, Shao T, Song M, et al. MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer［J］. Mol Cancer, 2020, 19(1): 51.
|
|
|
|
